MOSCOW, February 2. /TASS/. The World Health Organization (WHO) welcomes the fact that vaccine developers worldwide share results of their research with the scientific community. The publication of the results of Phase Three clinical trials of the Russian Sputnik V vaccine in the Lancet medical journal is good news, Melita Vujnovic, WHO representative in Russia, told the Russia-1 TV channel on Tuesday.

"The WHO welcomes the fact that all developers and manufacturers of vaccines share with the scientific community through such publications like in the Lancet journal. This is very good news," she said.

Earlier, the Lancet published the results of Phase Three clinical trials of the Russian vaccine according to which it is one of the safest and most effective ones worldwide. The efficacy of the preparation amounted to 91.6%, among volunteers over 60 - to 91.8%. Antibodies to the coronavirus after inoculation with Sputnik V were detected in 98% of volunteers.